EU
Prof. Dr. Dr. Fred Harms
Head of Institute for Preventive Medicine and Health Services Research, Sigmund Freud Private University, Vienna
Prof. Dr. Dr. Fred Harms
Head of Institute for Preventive Medicine and Health Services Research, Sigmund Freud Private University, Vienna
KLOUD
Scientific Advocate
In addition to his numerous professional activities and memberships, Prof. Dr. Dr. Fred Harms is a strong supporter of KLOUD and an integral part of the CENTROPIX Science Board.
Prof. Dr. Dr. Fred Harms studied biochemistry and medicine from 1986 to 1996 at the University of Witten/Herdecke, the University of Münster, the M.D. Anderson Cancer Center, Houston, Texas, USA and the University of Bangkok, graduating with an MD/PhD in tumor immunology/oncology. From 1997 to 1999, he was a lecturer in Innovation Management in Life Sciences at the Technical University of Darmstadt, Germany, and from 2000 to 2004, he was a lecturer in Health Care Management at the Technical University of Berlin, Germany.
From 2005 to 2007, he was a lecturer in Health Care Business Management at the University of Hamburg. From 2008 to 2009, he was Scientific Director for Pharmaceutical Business Management at the Center for Healthcare Management at the University of Krems and Chairman of the Center from 2010 to 2012. He taught as a Professor of Healthcare Management at the Mayes College of Healthcare Business and Policy at the University of Philadelphia, USA. Since 2013, he has headed the Institute for Preventive Medicine and Health Services Research together with Prof. Dr. Dorothee Gänshirt at Sigmund Freud Private University Vienna. The Institute works in cooperation with various European health institutions on developing strategies for prevention, compliance, and disease management of chronic diseases and evaluating potential benefits of medical innovations for patient care. In addition to his university activities, he was Director Oncology and Global Project Manager at Merck KGaA in Darmstadt respectively at Imclone NY, USA, from 1996 to 2002. He was responsible for developing Erbitux, a chimeric monoclonal antibody for treating colorectal cancer. From 2002 to 2003 he was Vice President of OncoScore (Novartis-Venture Basel) and Consultant of the Tumor Bank of the University Hospital Basel, and from 2004 to 2014 member of the Executive Board of the Health Care Competence Center (HC3) in Basel and since 2016 founder and member of the Executive Board of Beneganic Organic Vitamins in Zurich. Since 2020, he has been a member of the Executive Board of Beneganic AG in Pfäffikon SZ. In 2020, Beneganic AG was awarded the Innovation Award 2020/2021 as Top Innovator and Award Winner – Future made in Switzerland for its research in the field of nutraceuticals. In 2019, Prof. Harms was accredited as a psycho-oncologist after training by the Institute for Psycho-Oncological Training Cologne in cooperation with the German Cancer Society.
Fred Harms is the author of about 220 publications, book chapters, and lectures at scientific congresses.
From 2005 to 2007, he was a lecturer in Health Care Business Management at the University of Hamburg. From 2008 to 2009, he was Scientific Director for Pharmaceutical Business Management at the Center for Healthcare Management at the University of Krems and Chairman of the Center from 2010 to 2012. He taught as a Professor of Healthcare Management at the Mayes College of Healthcare Business and Policy at the University of Philadelphia, USA. Since 2013, he has headed the Institute for Preventive Medicine and Health Services Research together with Prof. Dr. Dorothee Gänshirt at Sigmund Freud Private University Vienna. The Institute works in cooperation with various European health institutions on developing strategies for prevention, compliance, and disease management of chronic diseases and evaluating potential benefits of medical innovations for patient care. In addition to his university activities, he was Director Oncology and Global Project Manager at Merck KGaA in Darmstadt respectively at Imclone NY, USA, from 1996 to 2002. He was responsible for developing Erbitux, a chimeric monoclonal antibody for treating colorectal cancer. From 2002 to 2003 he was Vice President of OncoScore (Novartis-Venture Basel) and Consultant of the Tumor Bank of the University Hospital Basel, and from 2004 to 2014 member of the Executive Board of the Health Care Competence Center (HC3) in Basel and since 2016 founder and member of the Executive Board of Beneganic Organic Vitamins in Zurich. Since 2020, he has been a member of the Executive Board of Beneganic AG in Pfäffikon SZ. In 2020, Beneganic AG was awarded the Innovation Award 2020/2021 as Top Innovator and Award Winner – Future made in Switzerland for its research in the field of nutraceuticals. In 2019, Prof. Harms was accredited as a psycho-oncologist after training by the Institute for Psycho-Oncological Training Cologne in cooperation with the German Cancer Society.
Fred Harms is the author of about 220 publications, book chapters, and lectures at scientific congresses.
In addition to his numerous professional activities and memberships, Prof. Dr. Dr. Fred Harms is a strong supporter of KLOUD and an integral part of the CENTROPIX Science Board.
Prof. Dr. Dr. Fred Harms studied biochemistry and medicine from 1986 to 1996 at the University of Witten/Herdecke, the University of Münster, the M.D. Anderson Cancer Center, Houston, Texas, USA and the University of Bangkok, graduating with an MD/PhD in tumor immunology/oncology. From 1997 to 1999, he was a lecturer in Innovation Management in Life Sciences at the Technical University of Darmstadt, Germany, and from 2000 to 2004, he was a lecturer in Health Care Management at the Technical University of Berlin, Germany.
From 2005 to 2007, he was a lecturer in Health Care Business Management at the University of Hamburg. From 2008 to 2009, he was Scientific Director for Pharmaceutical Business Management at the Center for Healthcare Management at the University of Krems and Chairman of the Center from 2010 to 2012. He taught as a Professor of Healthcare Management at the Mayes College of Healthcare Business and Policy at the University of Philadelphia, USA. Since 2013, he has headed the Institute for Preventive Medicine and Health Services Research together with Prof. Dr. Dorothee Gänshirt at Sigmund Freud Private University Vienna. The Institute works in cooperation with various European health institutions on developing strategies for prevention, compliance, and disease management of chronic diseases and evaluating potential benefits of medical innovations for patient care.
In addition to his university activities, he was Director Oncology and Global Project Manager at Merck KGaA in Darmstadt respectively at Imclone NY, USA, from 1996 to 2002. He was responsible for developing Erbitux, a chimeric monoclonal antibody for treating colorectal cancer. From 2002 to 2003 he was Vice President of OncoScore (Novartis-Venture Basel) and Consultant of the Tumor Bank of the University Hospital Basel, and from 2004 to 2014 member of the Executive Board of the Health Care Competence Center (HC3) in Basel and since 2016 founder and member of the Executive Board of Beneganic Organic Vitamins in Zurich. Since 2020, he has been a member of the Executive Board of Beneganic AG in Pfäffikon SZ. In 2020, Beneganic AG was awarded the Innovation Award 2020/2021 as Top Innovator and Award Winner – Future made in Switzerland for its research in the field of nutraceuticals. In 2019, Prof. Harms was accredited as a psycho-oncologist after training by the Institute for Psycho-Oncological Training Cologne in cooperation with the German Cancer Society.
Fred Harms is the author of about 220 publications, book chapters, and lectures at scientific congresses.
From 2005 to 2007, he was a lecturer in Health Care Business Management at the University of Hamburg. From 2008 to 2009, he was Scientific Director for Pharmaceutical Business Management at the Center for Healthcare Management at the University of Krems and Chairman of the Center from 2010 to 2012. He taught as a Professor of Healthcare Management at the Mayes College of Healthcare Business and Policy at the University of Philadelphia, USA. Since 2013, he has headed the Institute for Preventive Medicine and Health Services Research together with Prof. Dr. Dorothee Gänshirt at Sigmund Freud Private University Vienna. The Institute works in cooperation with various European health institutions on developing strategies for prevention, compliance, and disease management of chronic diseases and evaluating potential benefits of medical innovations for patient care.
In addition to his university activities, he was Director Oncology and Global Project Manager at Merck KGaA in Darmstadt respectively at Imclone NY, USA, from 1996 to 2002. He was responsible for developing Erbitux, a chimeric monoclonal antibody for treating colorectal cancer. From 2002 to 2003 he was Vice President of OncoScore (Novartis-Venture Basel) and Consultant of the Tumor Bank of the University Hospital Basel, and from 2004 to 2014 member of the Executive Board of the Health Care Competence Center (HC3) in Basel and since 2016 founder and member of the Executive Board of Beneganic Organic Vitamins in Zurich. Since 2020, he has been a member of the Executive Board of Beneganic AG in Pfäffikon SZ. In 2020, Beneganic AG was awarded the Innovation Award 2020/2021 as Top Innovator and Award Winner – Future made in Switzerland for its research in the field of nutraceuticals. In 2019, Prof. Harms was accredited as a psycho-oncologist after training by the Institute for Psycho-Oncological Training Cologne in cooperation with the German Cancer Society.
Fred Harms is the author of about 220 publications, book chapters, and lectures at scientific congresses.
International Memberships
Since 1994
New York Academy of Sciences
Since 1995
American Association for the Advancement of Science
2001 – 2005
Member of High-Technology Post-Graduate-Programs in Europe (EXIST)
Since 2003
American Society for Marketing and Management Advances
2005 – 2015
Vice President of European Health Care Foundation
Since 2006
Member of the Board of the International Prevention Organization (IPO Brussels)
2012 – 2014
Member of the Scientific Advisory Board of Roche AG (Diabetology Division)
International Memberships
Since 1994
New York Academy of Sciences
Since 1995
American Association for the Advancement of Science
2001 – 2005
Member of High-Technology Post-Graduate-Programs in Europe (EXIST)
Since 2003
American Society for Marketing and Management Advances
2005 – 2015
Vice President of European Health Care Foundation
Since 2006
Member of the Board of the International Prevention Organization (IPO Brussels)
2012 – 2014
Member of the Scientific Advisory Board of Roche AG (Diabetology Division)
Honors and Awards
1997 – 1991
Scholarship holder of the program for high potentials in life sciences of Hoechst AG Frankfurt
1992 – 1994
Scholarship holder of the Chemical Industry Study Fund of Henkel AG Düsseldorf
2005 – 2006
Merck, Sharp & Dohme Foundation Research Fellow, Whitehouse Station, NJ
Honors and Awards
1997 – 1991
Scholarship holder of the program for high potentials in life sciences of Hoechst AG Frankfurt
1992 – 1994
Scholarship holder of the Chemical Industry Study Fund of Henkel AG Düsseldorf
2005 – 2006
Merck, Sharp & Dohme Foundation Research Fellow, Whitehouse Station, NJ